4.6 Article

Antimicrobial photodynamic therapy as an alternative to systemic antibiotics: results from a double-blind, randomized, placebo-controlled, clinical study on type 2 diabetics

Journal

JOURNAL OF CLINICAL PERIODONTOLOGY
Volume 43, Issue 2, Pages 147-155

Publisher

WILEY
DOI: 10.1111/jcpe.12498

Keywords

antimicrobial photodynamic therapy; doxycycline; glycated haemoglobin A; interleukin-1; type 2 diabetes mellitus

Funding

  1. State of Sao Paulo Research Foundation (FAPESP) [2010/07326-0]
  2. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [10/07326-0] Funding Source: FAPESP

Ask authors/readers for more resources

AimThis double-blind, placebo-controlled clinical study compared multiple applications of the antimicrobial photodynamic therapy (aPDT) treatment protocol, to systemic doxycycline as adjuvant to scaling and root planing (SRP) on type 2 diabetic patients on clinical, systemic and immune-inflammatory outcomes. Materials and MethodsThirty patients with Hba1c >7% were allocated in two groups, SRP+Doxy (n=15) using systemic doxycycline 100mg/day (14days) and SRP+aPDT (n=15) with multiple applications (0, 3, 7 and 14days). Primary outcome was glycated haemoglobin levels (HbA1c). Clinical parameters: plaque score (PS), bleeding on probe, probing depth, suppuration, gingival recession, and clinical attachment level, percentage of pockets with desired clinical endpoint were measured at baseline and 3months after therapy. Cytokine profile was assessed at 0, 1 and 3month to measure IL1-, TNF- and TGF- on gingival crevicular fluid. ResultsNo significant difference was detected on HbA1c, between treatments. The SRP+aPDT group showed advantage on reducing moderate pockets in single-rooted teeth at 3months. SRP+aPDT presented better results at 3months on IL1- levels. There were no significant differences between TNF- and TGF-. ConclusionsBoth treatments improved clinical and systemic outcomes (Hba1c). SRP+aPDT performed better in moderate probing pocket depth on single-rooted teeth, reduced favourably inflammation in short term, and may be an alternative to systemic antibiotics. (Clinicaltrials.org ID NCT01595594).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available